» Articles » PMID: 39600973

Quantitative Measurement of the Kinase Activity of Wildtype ALPK1 and Disease-Causing ALPK1 Mutants Using Cell-Free Radiometric Phosphorylation Assays

Overview
Journal Bio Protoc
Specialty Biology
Date 2024 Nov 27
PMID 39600973
Authors
Affiliations
Soon will be listed here.
Abstract

ALPK1 is an atypical protein kinase that is activated during bacterial infection by ADP-heptose and phosphorylates TIFA to activate a cell signaling pathway. In contrast, specific mutations in ALPK1 allow it to also be activated by endogenous human nucleotide sugars such as UDP-mannose, leading to the phosphorylation of TIFA in the absence of infection. This protocol describes a quantitative, cell-free phosphorylation assay that can directly measure the catalytic activity of wildtype and disease-causing ALPK1 in the presence of different nucleotide sugars. In this method, overexpressed ALPK1 is first immunoprecipitated from the extracts of ALPK1 knockout HEK-Blue cells transfected with plasmids encoding either FLAG-tagged wildtype or mutant ALPK1, and then subjected to a radioactive phosphorylation assay in which the phosphorylation of purified GST-tagged TIFA by ALPK1 is quantified by measuring the incorporation of radioactivity derived from radiolabeled ATP. Key features • Quantitative measurement of protein kinase activity of wildtype and mutant ALPK1 in the presence or absence of different nucleotide sugars such as ADP-heptose and UDP-mannose. • Cell-free experimental setup overcoming the challenge of distinguishing constitutive activity and activation by endogenous mammalian metabolites in cell-based assays. • Requires approximately 50 µg of cell extract protein/reaction, allowing up to 150 assays to be performed from an extract prepared from a single 15 cm dish of transfected cells.

Citing Articles

Discovery and functional analysis of a novel ALPK1 variant in ROSAH syndrome.

Snelling T, Garnotel L, Jeru I, Tusseau M, Cuisset L, Perlat A Open Biol. 2024; 14(12):240260.

PMID: 39626775 PMC: 11614533. DOI: 10.1098/rsob.240260.

References
1.
Zhou P, She Y, Dong N, Li P, He H, Borio A . Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose. Nature. 2018; 561(7721):122-126. DOI: 10.1038/s41586-018-0433-3. View

2.
Williams L, Javed A, Sabri A, Morgan D, Huff C, Grigg J . ALPK1 missense pathogenic variant in five families leads to ROSAH syndrome, an ocular multisystem autosomal dominant disorder. Genet Med. 2019; 21(9):2103-2115. PMC: 6752478. DOI: 10.1038/s41436-019-0476-3. View

3.
Snelling T, Shpiro N, Gourlay R, Lamoliatte F, Cohen P . Co-ordinated control of the ADP-heptose/ALPK1 signalling network by the E3 ligases TRAF6, TRAF2/c-IAP1 and LUBAC. Biochem J. 2022; 479(20):2195-2216. PMC: 9704527. DOI: 10.1042/BCJ20220401. View

4.
Snelling T, Saalfrank A, Wood N, Cohen P . ALPK1 mutants causing ROSAH syndrome or Spiradenoma are activated by human nucleotide sugars. Proc Natl Acad Sci U S A. 2023; 120(50):e2313148120. PMC: 10723048. DOI: 10.1073/pnas.2313148120. View

5.
Kozycki C, Kodati S, Huryn L, Wang H, Warner B, Jani P . Gain-of-function mutations in cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome. Ann Rheum Dis. 2022; 81(10):1453-1464. PMC: 9484401. DOI: 10.1136/annrheumdis-2022-222629. View